

FIGURE 1





FIGURE 2

A



B





FIGURE 2 continued

C



D




FIGURE 3




FIGURE 4

Sample	Peak 1 Area (%)	Peak 2 Area (%)	Peak 3 Area (%)	HPLC High- Man%	MALDI- TOF High- Man%	Reference High-Man%
Cetuximab						
Cetuximab + IdeS	-	39.7	58.6	15.7	19.3	14 ⁽²⁾
Cetuximab + IdeS + EndoS	11.4	43.0	44.4			
Cetuximab + IdeS + EndoS2	1.8	36.0	60.1			
Adalimumab						
Adalimumab + IdeS	1.8	15.0	78.3	9.0	5.1	-
Adalimumab + IdeS + EndoS	2.9	21.9	70.4			
Adalimumab + IdeS + EndoS2	2.0	14.7	79.4			
Panitumumab						
Panitumumab + IdeS	2.2	10.9	79.1	11.4	13.2	10.6 ⁽³⁾)
Panitumumab + IdeS + EndoS	4.3	17.1	70.3			
Panitumumab + IdeS + EndoS2	2.5	9.2	81.7			
Denosumab						
Denosumab + IdeS	2.2	7.6	82.4	6.3	3.9	-
Denosumab + IdeS + EndoS	3.3	14.2	75.3			
Denosumab + IdeS + EndoS2	2,5	9.7	81.6			

FIGURE 5




FIGURE 6

